Lieber; Andre

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lieber; Andre.The latest application filed is for "recombinant ad35 vectors and related gene therapy improvements".

Company Profile

4.14.15

Lieber; Andre - Seattle WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Recombinant Ad35 Vectors And Related Gene Therapy Improvements App 20220257796 - Kiem; Hans-Peter ; et al.	2022-08-18
Detection Of Desmoglein-2 In Cancers Of Epithelial Origin App 20220229061 - CARTER; Darrick ; et al.	2022-07-21
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20220127308 - LIEBER; Andre ; et al.	2022-04-28
Desmoglein 2 (DSG2) binding proteins and uses therefor Grant 11,248,028 - Lieber , et al. February 15, 2	2022-02-15
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20200277336 - LIEBER; Andre ; et al.	2020-09-03
Desmoglein 2 (DSG2) binding proteins and uses therefor Grant 10,611,803 - Lieber , et al.	2020-04-07
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20190092819 - LIEBER; Andre ; et al.	2019-03-28
Desmoglein 2 (DSG2) binding proteins and uses therefor Grant 10,150,798 - Lieber , et al. Dec	2018-12-11
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20170247419 - LIEBER; Andre ; et al.	2017-08-31
Desmoglein 2 (DSG2) binding proteins and uses therefor Grant 9,688,727 - Lieber , et al. June 27, 2	2017-06-27
In vivo Gene Engineering with Adenoviral Vectors App 20170037431 - LIEBER; Andre ; et al.	2017-02-09
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20160257721 - LIEBER; Andre ; et al.	2016-09-08
Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) Grant 9,200,041 - Lieber , et al. December 1, 2	2015-12-01
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor App 20150246949 - Lieber; Andre ; et al.	2015-09-03
Compositions and methods for modulating the activity of complement regulatory proteins on target cells Grant 8,753,639 - Lieber , et al. June 17, 2	2014-06-17
Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) Grant 8,722,853 - Lieber , et al. May 13, 2	2014-05-13
Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) App 20140107014 - Lieber; Andre ; et al.	2014-04-17
Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) App 20110305634 - Lieber; Andre ; et al.	2011-12-15
Compositions And Methods For Modulating The Activity Of Complement Regulatory Proteins On Target Cells App 20100255011 - Lieber; Andre ; et al.	2010-10-07
Capsid-modified adenovirus vectors and methods of using the same App 20060281090 - Lieber; Andre ; et al.	2006-12-14
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration Grant 7,094,398 - Lieber , et al. August 22, 2	2006-08-22
Adenovirus vectors for immunotherapy App 20060073123 - Mi; Jie ; et al.	2006-04-06
Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof Grant 6,686,196 - Lieber , et al. February 3, 2	2004-02-03
Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof App 20020037280 - Lieber, Andre ; et al.	2002-03-28
Methods and compositions for enhanced stability of non-adenoviral DNA Grant 6,132,989 - Kay , et al. October 17, 2	2000-10-17
Ribozymes for treating hepatitis C Grant 6,107,028 - Kay , et al. August 22, 2	2000-08-22
Ribozymes for treating hepatitis C Grant 6,107,027 - Kay , et al. August 22, 2	2000-08-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.